López-Talavera J C, Levitzki A, Martínez M, Gazit A, Esteban R, Guardia J
Liver Unit, Hospital Vall d'Hebrón, Barcelona, Spain.
J Clin Invest. 1997 Aug 1;100(3):664-70. doi: 10.1172/JCI119578.
Tumor necrosis factor-alpha (TNF) causes vasodilatation and a hyperdynamic state by activating nitric oxide (NO) synthesis. Tyrphostins, specific inhibitors of protein tyrosine kinase (PTK), block the signaling events induced by TNF and NO production. A hyperdynamic circulatory syndrome (HCS) is often observed in portal hypertension (PHT). TNF and NO seem to mediate these hemodynamic changes. The aim of this work was to study the effect of PTK inhibition on the systemic and portal hemodynamics, TNF and NO production, in cirrhotic rats with portal hypertension. Rats with liver cirrhosis induced by chronic inhalation of carbon tetrachloride were used. Animals were treated daily with tyrphostin AG 126 (alpha-cyano-(3-hydroxy-4-nitro) cinnamonitrile) or placebo for 5 d. Mean arterial pressure (MAP), heart rate (HR), and portal pressure (PP) were measured by indwelling catheters. Cardiac output (CI) and stroke volume (SV) were estimated by thermodilution, systemic vascular resistance (SVR) was calculated (MAP/CI), and portal systemic shunting (PSS) was quantitated using radioactive microspheres. Serum and mesenteric lymph node (MLN) TNF levels were measured using an immunoassay kit, and serum NOx was determined photometrically by its oxidation products. The AG 126-treated group showed a statistically significant increase in MAP and SVR, and decreases in CI, SV, MLN TNF, and serum NO oxidation products nitrite and nitrate (NOx) in comparison with the placebo-treated rats. No significant differences were noticed in HR, PP, PSS, or serum TNF. Significant correlations were observed between MAP and NOx, MAP and MLN TNF, PSS and NOx, and serum TNF and serum NOx. The HCS observed in PHT seems to be mediated, at least in part, by TNF and NO by the activation of PTKs and their signaling pathways. PTK activity inhibition ameliorates the hyperdynamic abnormalities that characterize animals with cirrhosis and PHT.
肿瘤坏死因子-α(TNF)通过激活一氧化氮(NO)合成导致血管舒张和高动力状态。酪氨酸磷酸化酶抑制剂是蛋白酪氨酸激酶(PTK)的特异性抑制剂,可阻断TNF诱导的信号转导事件和NO生成。在门静脉高压症(PHT)中常观察到高动力循环综合征(HCS)。TNF和NO似乎介导了这些血流动力学变化。本研究的目的是探讨PTK抑制对门静脉高压肝硬化大鼠全身和门静脉血流动力学、TNF及NO生成的影响。采用慢性吸入四氯化碳诱导肝硬化的大鼠。动物每天用酪氨酸磷酸化酶抑制剂AG 126(α-氰基-(3-羟基-4-硝基)肉桂腈)或安慰剂治疗5天。通过留置导管测量平均动脉压(MAP)、心率(HR)和门静脉压力(PP)。通过热稀释法估算心输出量(CI)和每搏输出量(SV),计算体循环血管阻力(SVR)(MAP/CI),并使用放射性微球定量门静脉体循环分流(PSS)。使用免疫分析试剂盒测量血清和肠系膜淋巴结(MLN)中的TNF水平,通过其氧化产物光度法测定血清NOx。与安慰剂治疗组大鼠相比,AG 126治疗组的MAP和SVR有统计学意义的升高,CI、SV、MLN TNF以及血清NO氧化产物亚硝酸盐和硝酸盐(NOx)降低。在HR、PP、PSS或血清TNF方面未观察到显著差异。在MAP与NOx、MAP与MLN TNF、PSS与NOx以及血清TNF与血清NOx之间观察到显著相关性。PHT中观察到的HCS似乎至少部分是由TNF和NO通过激活PTK及其信号通路介导的。抑制PTK活性可改善肝硬化和PHT动物所特有的高动力异常。